Press Releases
Public Relations: Andrew Noble
DNAnexus Customer Satisfaction Reaches 90% Amid Platform Expansion Into AI-Driven Discovery
Accelerated Cure Project for MS Launches the ACP Data Challenge Pilot, a New Initiative to Explore One of the World's Most Comprehensive MS Research Ecosystems
DNAnexus Scales AI-Driven Capabilities
DNAnexus Wins MedTech Breakthrough’s PharmaTech Innovation Award
Longitude Prize on ALS Announces Stage 1 Discovery Award Winners
News
Why Data Infrastructure, Not Models, Drives Life Sciences AI
The life sciences industry has spent the better part of three years chasing model performance. Bigger foundation models, more parameters, better fine-tuning pipelines. The implicit assumption has been that if you get the algorithms right, the rest follows. DNAnexus CEO Thomas Laur theorizes that the primary obstacle to AI-driven drug discovery is not model quality or algorithmic sophistication, but rather the inability to get scientific data into a state that AI systems can actually consume. The evidence supports him.
Do you expect continued movement away from one-stop-shop outsourcing toward deeper modality-specific expertise?
Immunai, AstraZeneca Expand Partnership, Rancho Biosciences Releases Multi-omics Datasets, Dotmatics AI Co-Scientist
Programming biology: next-gen AI firms raise billions to design better medicines
Faster drug discovery, optimized drug design, even programmable therapeutics: AI is impacting R&D. Data and development bottlenecks remain.
DNAnexus AI Products
"Collaboration is vital to advancing scientific discovery. We are excited to partner with Microsoft and DNAnexus to create infrastructure and tools to share data and accelerate progress toward finding cures for pediatric cancer and other life-threatening diseases."
James R. Downing
President & CEO
St. Judes Children’s Research Hospital